You are here: All Products  > Ablaze Pharma Acquires China Rights to Targeted Radiotherapy Drug for Liver Cancers

Ablaze Pharma Acquires China Rights to Targeted Radiotherapy Drug for Liver Cancers

Price: $5.00
Available

Get instant access to this article for unlimited viewing and/or downloading for seven days.


Back to products